Sehra ST, Kelly A, Baker JF, Derk CT: Predictors of inpatient mortality in patients with systemic sclerosis: a case control study. Clinical Rheumatology 35(6): 1631-5, Jun 2016.
Khanna D, Denton CP, Merkel PA, Krieg T, Le Brun FO, Marr A, Papadakis K, Pope J, Mattuci-Cerinic M, Furst DE, DUAL-1 investigators, DUAL-2 investigators: Effect of Macitentan on the development of new ischemic digital ulcers in Patients with Systemic Sclerosis: DUAL-1 and DUAL-2 randomized clinical trials. JAMA 315(18): 1975-88, May 2016.
Hinchcliff M, Khanna S, Hsu VM, Lee J, Almagor O, Chang RW, Steen V, Chung L, PHAROS investigators: Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry. Seminar of Arthritis and Rheumatology 45(3): 309-14, Dec 2015.
Kelly, A; Derk CT: Anti-RNA polymerase III antibodies in Systemic Sclerosis. Open Journal of Rheumatology and Autoimmune Diseases 5: 81-86, Aug 2015.
Abraham M, Derk CT: Anti-Ribosomal- P antibodies in lupus nephritis, neuropsychiatric lupus, lupus hepatitis and Chaga's disease: promising yet limited in clinical utility. Rheumatol Int 35(1): 27-33, Jan 2015.
Sehra, S; Kelly, A, Baker J, Derk CT: Predictors of inpatient mortality in patient with systemic sclerosis: a case control study. American College of Rheumatology, Annual Scientific Meeting, Boston. Poster Presentation Nov 2014.
Mecoli C, Purohit S, Sandorfi N, Derk CT: Mortality, Recurrence, and hospital course of patients with systemic sclerosis-related acute intestinal pseudo-obstruction. J Rheumatol 41(10): 2049-54, Oct 2014.
Hsu VM, Chung L, Hummers LK, Wigley F, Simms R, Bolster M, Silver R, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Alkassab F, Steen VD. : Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study.
Semin Arthritis Rheum 44(1): 55-62, Aug 2014.
Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankle S, Oddis CV, denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-sStine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Prodman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matterson EL, Brown KK, Seibold JR, and CTD-ILD Special Interest Group. : Connective tissue disease related interstitial lung disease and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax 69(5): 428-36, May 2014.
Saketkoo LA, Mittoo S, Frankle S, LeSage D, Sarver C, Phillips K, strand V, Matterson EL and OMERACT Connective Tissue Disease-Interstitial Lung Diseases Working Group. : Reconciling Healthcare Professional and Patient Perspectives in the Development of Disease Activity and Response Criteria in Connective Tissue Disease-related Interstitial Lung Diseases. J Rheumatol 41(4): 792-8, April 2014.
back to top
Last updated: 09/27/2016
The Trustees of the University of Pennsylvania